Understanding the COVID-19 ‘Cicada’ Variant: What You Require to Recognize

As spring transitions into summer, health officials are monitoring a newly identified SARS-CoV-2 variant nicknamed “Cicada” due to its pattern of emergence after a period of low circulation. Scientifically designated as BA.3.2, this Omicron subvariant has drawn attention for its significant genetic mutations, particularly in the spike protein, which may affect how well existing immunity from vaccines or prior infection protects against it. Although currently not the dominant strain in the United States, its steady spread across multiple states warrants awareness without alarm.

What Is the BA.3.2 ‘Cicada’ Variant?

The BA.3.2 variant, informally called “Cicada,” is a descendant of the Omicron lineage of SARS-CoV-2. It was first identified in November 2024 and has since been detected in at least 23 countries and more than half of U.S. States. The name “Cicada” was coined by evolutionary biologist T. Ryan Gregory, Ph.D., of the University of Guelph, reflecting the variant’s pattern of lying relatively dormant before re-emerging—much like the insect that spends years underground before surfacing in large numbers.

BA.3.2 is characterized by a high number of mutations, with estimates ranging from 70 to 75 genetic changes compared to the original virus. Many of these mutations are located in the spike protein, the part of the virus that binds to human cells and is the primary target of immune responses generated by vaccination or prior infection. According to Andrew Pekosz, Ph.D., a virologist at the Johns Hopkins Bloomberg School of Public Health, these alterations may reduce the effectiveness of existing immunity, though they do not necessarily eliminate it entirely.

Where Has the Cicada Variant Been Detected?

As of early April 2026, the Centers for Disease Control and Prevention (CDC) reported that BA.3.2 had been identified in more than half of U.S. States. Earlier data from February 2026 indicated detection in at least 25 states through clinical samples and wastewater surveillance. Internationally, the variant has been found in at least 23 countries. The World Health Organization (WHO) classified BA.3.2 as a “variant under monitoring” in December 2025 due to its genetic distinctiveness and potential immune evasion properties.

Wastewater surveillance has played a key role in tracking the variant’s spread. As of early February 2026, BA.3.2 was detected in nasal swabs from four travelers, three airplane wastewater samples, clinical samples from five patients, and 132 wastewater samples from 25 U.S. States, according to the CDC. This environmental monitoring helps public health officials assess transmission trends even when clinical testing is uneven.

Are Symptoms Different?

Currently, there is no evidence that infection with the BA.3.2 variant causes different or more severe symptoms compared to other circulating Omicron subvariants. Symptoms remain consistent with those seen throughout the pandemic: fever, cough, shortness of breath, sore throat, congestion, fatigue, and in some cases, gastrointestinal issues like nausea or diarrhea. The CDC and WHO have not reported a nationwide increase in severe disease, hospitalizations, or deaths linked specifically to BA.3.2.

William Schaffner, M.D., professor of infectious diseases at Vanderbilt University, noted that while the variant is gaining attention, it has not yet displaced dominant strains. “Whether it will push itself to the front of the line remains to be seen,” he stated. Celine Gounder, M.D., epidemiologist and editor-at-large for KFF Health News, added that there is no current indication that BA.3.2 leads to more severe outcomes.

How Effective Are Vaccines and Prior Immunity?

Research suggests that BA.3.2 may partially evade immunity generated by prior infection or vaccination due to its extensive spike protein mutations. A study published in the CDC’s Morbidity and Mortality Weekly Report found that the variant’s genetic changes could reduce recognition by antibodies. However, experts emphasize that immune protection is not all-or-nothing. Vaccines and prior infection still offer substantial defense against severe illness, even if their ability to block infection entirely is diminished.

Celine Gounder noted that while the current vaccines may be less effective at preventing infection with BA.3.2, they continue to provide meaningful protection against serious outcomes. William Schaffner added that immune evasion does not equate to immune escape—meaning the body’s defenses are weakened but not rendered useless.

What Should the Public Do?

Public health recommendations remain consistent: stay up to date with COVID-19 vaccinations, including booster doses when eligible; consider wearing masks in crowded indoor settings during periods of high transmission; practice great hand hygiene; and stay home when sick to prevent spreading respiratory illnesses. Individuals who are immunocompromised, elderly, or have underlying health conditions should consult their healthcare providers about additional precautions.

The CDC continues to monitor BA.3.2 alongside other variants through genomic sequencing, wastewater analysis, and clinical surveillance. As of now, no changes to public health guidance have been issued specifically in response to the Cicada variant.

Looking Ahead

The emergence of BA.3.2 underscores the ongoing evolution of SARS-CoV-2. While the variant has not yet caused a surge in severe illness, its genetic profile warrants continued vigilance. Experts agree that the virus will likely continue to mutate, and periodic updates to vaccines may be necessary to maintain optimal protection—similar to the annual approach used for influenza.

For now, the appearance of the Cicada variant serves as a reminder that COVID-19 remains part of the respiratory illness landscape, but one that can be managed through informed personal choices and sustained public health monitoring.